Experimental drug Brentuximab Vedotin (SGN-35) achieved tumor volume reductions in 94% of Relapsed or Refractory Hodgkin Lymphoma patients while 34% of them achieved complete remission, Seattle Genetics reported after completing a Pivotal Clinical Trial. The company expects to submit the...